SGPL1 and lysosomal lipid storage disorder: In aggregate, our findings demonstrate that AAV-SPL treatment delivered early in life can avert the development of nephrosis, neurobehavioral deficits, lipidosis, and aberrant inflammatory signaling, enabling long-term survival in a mouse model of SPLIS.